FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912199729> ?p ?o ?g. }

• W2912199729 endingPage "1351" @default.
• W2912199729 startingPage "1340" @default.
• W2912199729 abstract "Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated dose ( MTD ) and/or highest studied dose being safe. Secondary objectives included safety, pharmacokinetics and preliminary antitumor activity. Dose escalation was guided by a Bayesian Logistic Regression Model dependent on dose‐limiting toxicities ( DLT ) in cycle 1. Of 44 adult Japanese patients with confirmed advanced solid tumors enrolled, 29 received capmatinib capsules (doses ranging from 100 mg once daily [q.d.] to 600 mg twice daily [b.i.d.]) and 15 received tablets (200 mg b.i.d. and 400 mg b.i.d.). DLT occurred in two patients: grade 2 suicidal ideation (600 mg b.i.d. capsule) and grade 3 depression (400 mg b.i.d. tablet). MTD was not reached. The highest studied dose determined to be safe as tablet was 400 mg b.i.d., whereas it is not yet determined for capsules. Most common adverse events suspected to be drug‐related were increased blood creatinine, nausea, decreased appetite, vomiting and diarrhea. Following repeated daily dosing up to day 15 by q.d. or b.i.d. regimen using capsules, median time to reach maximum plasma drug concentration ( T max ) was 1.0‐4.0 hours; absorption was more rapid after dosing using tablets, with median T max of 1.0 hour on both days 1 and 15. Eight patients had a best overall response of stable disease. These data support further clinical development of capmatinib." @default.
• W2912199729 created "2019-02-21" @default.
• W2912199729 creator A5001115937 @default.
• W2912199729 creator A5017400559 @default.
• W2912199729 creator A5021868399 @default.
• W2912199729 creator A5043738572 @default.
• W2912199729 creator A5052865562 @default.
• W2912199729 creator A5053468733 @default.
• W2912199729 creator A5055212193 @default.
• W2912199729 creator A5064272098 @default.
• W2912199729 creator A5067259938 @default.
• W2912199729 creator A5068676079 @default.
• W2912199729 creator A5076317422 @default.
• W2912199729 creator A5090048812 @default.
• W2912199729 date "2019-02-20" @default.
• W2912199729 modified "2023-10-16" @default.
• W2912199729 title "Phase I dose‐escalation study of capmatinib (<scp>INC</scp>280) in Japanese patients with advanced solid tumors" @default.
• W2912199729 cites W1974918522 @default.
• W2912199729 cites W1995277013 @default.
• W2912199729 cites W1998971866 @default.
• W2912199729 cites W2042990006 @default.
• W2912199729 cites W2045985885 @default.
• W2912199729 cites W2048097275 @default.
• W2912199729 cites W2093613683 @default.
• W2912199729 cites W2096844786 @default.
• W2912199729 cites W2099753997 @default.
• W2912199729 cites W2101441514 @default.
• W2912199729 cites W2105333585 @default.
• W2912199729 cites W2111424734 @default.
• W2912199729 cites W2121262970 @default.
• W2912199729 cites W2122895515 @default.
• W2912199729 cites W2133734904 @default.
• W2912199729 cites W2136390065 @default.
• W2912199729 cites W2138309116 @default.
• W2912199729 cites W2154402764 @default.
• W2912199729 cites W2160212814 @default.
• W2912199729 cites W2163375553 @default.
• W2912199729 cites W2169624569 @default.
• W2912199729 cites W2170259414 @default.
• W2912199729 cites W2597411122 @default.
• W2912199729 cites W2681380026 @default.
• W2912199729 cites W2807419944 @default.
• W2912199729 cites W2887029617 @default.
• W2912199729 cites W2890949287 @default.
• W2912199729 doi "https://doi.org/10.1111/cas.13956" @default.
• W2912199729 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6447844" @default.
• W2912199729 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30724423" @default.
• W2912199729 hasPublicationYear "2019" @default.
• W2912199729 type Work @default.
• W2912199729 sameAs 2912199729 @default.
• W2912199729 citedByCount "29" @default.
• W2912199729 countsByYear W29121997292019 @default.
• W2912199729 countsByYear W29121997292020 @default.
• W2912199729 countsByYear W29121997292021 @default.
• W2912199729 countsByYear W29121997292022 @default.
• W2912199729 countsByYear W29121997292023 @default.
• W2912199729 crossrefType "journal-article" @default.
• W2912199729 hasAuthorship W2912199729A5001115937 @default.
• W2912199729 hasAuthorship W2912199729A5017400559 @default.
• W2912199729 hasAuthorship W2912199729A5021868399 @default.
• W2912199729 hasAuthorship W2912199729A5043738572 @default.
• W2912199729 hasAuthorship W2912199729A5052865562 @default.
• W2912199729 hasAuthorship W2912199729A5053468733 @default.
• W2912199729 hasAuthorship W2912199729A5055212193 @default.
• W2912199729 hasAuthorship W2912199729A5064272098 @default.
• W2912199729 hasAuthorship W2912199729A5067259938 @default.
• W2912199729 hasAuthorship W2912199729A5068676079 @default.
• W2912199729 hasAuthorship W2912199729A5076317422 @default.
• W2912199729 hasAuthorship W2912199729A5090048812 @default.
• W2912199729 hasBestOaLocation W29121997291 @default.
• W2912199729 hasConcept C112705442 @default.
• W2912199729 hasConcept C126322002 @default.
• W2912199729 hasConcept C197934379 @default.
• W2912199729 hasConcept C2777288759 @default.
• W2912199729 hasConcept C2780580376 @default.
• W2912199729 hasConcept C2780852908 @default.
• W2912199729 hasConcept C2781413609 @default.
• W2912199729 hasConcept C71924100 @default.
• W2912199729 hasConcept C90924648 @default.
• W2912199729 hasConcept C98274493 @default.
• W2912199729 hasConceptScore W2912199729C112705442 @default.
• W2912199729 hasConceptScore W2912199729C126322002 @default.
• W2912199729 hasConceptScore W2912199729C197934379 @default.
• W2912199729 hasConceptScore W2912199729C2777288759 @default.
• W2912199729 hasConceptScore W2912199729C2780580376 @default.
• W2912199729 hasConceptScore W2912199729C2780852908 @default.
• W2912199729 hasConceptScore W2912199729C2781413609 @default.
• W2912199729 hasConceptScore W2912199729C71924100 @default.
• W2912199729 hasConceptScore W2912199729C90924648 @default.
• W2912199729 hasConceptScore W2912199729C98274493 @default.
• W2912199729 hasFunder F4320310388 @default.
• W2912199729 hasIssue "4" @default.
• W2912199729 hasLocation W29121997291 @default.
• W2912199729 hasLocation W29121997292 @default.
• W2912199729 hasLocation W29121997293 @default.
• W2912199729 hasOpenAccess W2912199729 @default.
• W2912199729 hasPrimaryLocation W29121997291 @default.
• W2912199729 hasRelatedWork W2004325424 @default.

• next